SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...


Istari Oncology is a clinical-stage biotechnology company focused on developing innovative immuno-oncology platforms for the treatment of solid tumors, including glioblastoma and melanoma.